Colorado Responds to MDR-TB:
A Meeting To Foster Collaborative Research on the Front Range

Keynote Speaker and Plenary Talk PowerPoint Presentations: Keynote Speaker: XDR-TB, AIDS and the Future of TB Control-an Apocalyptic Tale: Michael D. Iseman, M.D.; National Jewish Medical and Research Center
CFAR and Building Opportunities for Colorado's Infectious Disease Community: Edward N. Janoff, M.D.; Colorado Center for AIDS Research (CFAR); Division of Infectious Diseases, UCD
Drug Resistant Tuberculosis: Diagnostic Needs and Priorities: Charles L. Daley, M.D.; National Jewish Medical and Research Center
Therapeutics: Targets for Early Drug Discovery: Dean Crick, Ph.D.; Colorado State University
Preclinical Testing of Experimental Compounds against M. Tuberculosis: Anne Lenaerts, Ph.D.; Colorado State University
New Microbiologic and Immunologic Markers of Response to TB Therapy a Critical Need: C. Robert Horsburgh, Jr., M.D., M.U.S.; Boston University School of Public Health and CFAR Visiting Professor
How Do These Drugs Work, Anyway? PK, PD, and Treatment Outcomes: Charles Peloquin, PharmD; National Jewish Medical and Research Center
Potential for Vaccination Against Drug Resistant TB: Ian Orme, Ph.D.; Colorado State University
Concluding Remarks: Identification of Joint Research Programs: Patrick J. Brennan, Ph.D.; Colorado State University